Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Recommendation of "Buy" from Brokerages

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) have been assigned an average rating of "Buy" from the ten research firms that are currently covering the stock, MarketBeat reports. Ten analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokerages that have covered the stock in the last year is $62.22.

Several equities analysts have recently commented on the stock. UBS Group lowered their target price on shares of Jasper Therapeutics from $38.00 to $33.00 and set a "buy" rating on the stock in a report on Tuesday, May 13th. Oppenheimer decreased their price target on shares of Jasper Therapeutics from $80.00 to $65.00 and set an "outperform" rating on the stock in a research note on Thursday, May 15th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $40.00 price target on shares of Jasper Therapeutics in a research note on Tuesday, March 11th.

Jasper Therapeutics Price Performance

Shares of JSPR stock traded down $0.05 during mid-day trading on Friday, hitting $5.45. The company had a trading volume of 177,789 shares, compared to its average volume of 296,407. Jasper Therapeutics has a 52-week low of $3.13 and a 52-week high of $26.84. The stock's 50 day moving average price is $4.55 and its 200-day moving average price is $9.60. The company has a market capitalization of $81.87 million, a P/E ratio of -1.15 and a beta of 2.74.

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.24). On average, equities research analysts expect that Jasper Therapeutics will post -4.47 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Wellington Management Group LLP increased its position in Jasper Therapeutics by 13.9% during the fourth quarter. Wellington Management Group LLP now owns 27,069 shares of the company's stock valued at $579,000 after acquiring an additional 3,310 shares during the last quarter. JPMorgan Chase & Co. increased its position in Jasper Therapeutics by 239.8% during the third quarter. JPMorgan Chase & Co. now owns 16,391 shares of the company's stock valued at $308,000 after acquiring an additional 11,567 shares during the last quarter. Deutsche Bank AG grew its holdings in shares of Jasper Therapeutics by 30.0% in the fourth quarter. Deutsche Bank AG now owns 170,695 shares of the company's stock worth $3,649,000 after purchasing an additional 39,436 shares during the last quarter. Wells Fargo & Company MN grew its holdings in shares of Jasper Therapeutics by 106.7% in the fourth quarter. Wells Fargo & Company MN now owns 7,415 shares of the company's stock worth $159,000 after purchasing an additional 3,828 shares during the last quarter. Finally, Simplify Asset Management Inc. bought a new position in shares of Jasper Therapeutics in the fourth quarter worth about $428,000. Institutional investors own 79.85% of the company's stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.